Breaking News
Get 40% Off 0
👀 Reveal Warren Buffett's stock picks that are beating the S&P 500 by +174.3% Get 40% Off
Close

Morphosys AG O.N. (MORG)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
65.0000 -0.1200    -0.18%
16:35:25 - Closed. Currency in EUR ( Disclaimer )
  • Volume: 259,060
  • Bid/Ask: 65.0000 / 65.0200
  • Day's Range: 64.8800 - 65.1800
Type:  Equity
Market:  Germany
ISIN:  DE0006632003 
WKN:  663200
Morphosys AG 65.0000 -0.1200 -0.18%

Morphosys AG O.N. Company Profile

 
Read the Morphosys AG company profile to learn more about the business and the management team. View employee data, company address and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

544

Equity Type

ORD

MorphoSys AG, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. It offers Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B-cell lymphoma, follicular lymphoma, and marginal zone lymphoma. The company also develops Pelabresib, a small molecule to treat myelofibrosis; Felzartamab, an antibody directed against CD38 for the treatment of anti-PLA2R-positive membranous nephropathy, an autoimmune disease; and CPI-0209, a small molecule to promote anti-tumor activity by inhibiting EZH2 and EZH1. In addition, it develops Gantenerumab, an antibody for the treatment of Alzheimer’s diseases; and Otilimab, an antibody for rheumatoid arthritis. The company has a regional licensing agreement with I-Mab Biopharma to develop and commercialize felzartamab in China, Taiwan, Hong Kong, and Macau; a strategic alliance with the LEO Pharma; a joint collaboration and license agreement with Incyte Corporation to develop and commercialize MorphoSys investigational compound tafasitamab; and a clinical collaboration with Incyte Corporation and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. MorphoSys AG was founded in 1992 and is headquartered in Planegg, Germany.

Contact Information

Address Semmelweisstrasse 7
Planegg, 82152
Germany
Phone 49 89 89927 0
Fax 49 89 89927 222

Top Executives

Name Age Since Title
Marc Cluzel 66 2012 Independent Chairman of the Supervisory Board
Michael Brosnan 66 2018 Independent Member of the Supervisory Board
Krisja Vermeylen 59 2017 Independent Member of the Supervisory Board
George S. Golumbeski 64 2018 Independent Deputy Chairman of Supervisory Board
Sharon Curran 54 2019 Independent Member of Supervisory Board
Raymond W. Sweet - 2016 Member of Scientific Advisory Board
Gunther R. Adolf - 2016 Member of Scientific Advisory Board
Sergio A. Quezada 46 2016 Member of Scientific Advisory Board
Bruce D. Cheson - 2016 Member of Scientific Advisory Board
Andrew Cheng 56 2022 Independent Member of Supervisory Board
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

MORG Comments

Write your thoughts about Morphosys AG O.N.
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Bentley Man
Bentley Man Sep 06, 2022 12:00
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Buyout is not if, but when.
Mark Caple
Mark Caple Mar 28, 2022 8:21
Saved. See Saved Items.
This comment has already been saved in your Saved Items
This needs a good kick and it will move fast upwards soon if not may be stagnant for done time
Mark Caple
Mark Caple May 10, 2021 10:49
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Easily regain this lost ground
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email